Mumbai: Global pharma company, Glenmark Pharmaceuticals Limited, has recently announced that the company has received marketing approval for its fixed-dose combination nasal spray Ryaltris in 13.
Glenmark Pharmaceuticals has announced that it has received marketing approval for its fixed-dose combination nasal spray, Ryaltris, in 13 countries across the UK and EU. - News - PharmaTimes
- Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis - Ryaltris has been
Glenmark gets marketing approval for Ryaltris in 13 EU, UK countries outlookindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outlookindia.com Daily Mail and Mail on Sunday newspapers.